to evaluate the efficacy and safety of Targeted Radionuclide Therapy with n.c.a. 177Lu-Edotreotide in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NETs).
The trial is conducted worldwide in min. 12 countries at approx. 43 sites and is open for recruitment. Healthcare professionals who are interested in enrolling patients can find comprehensive background information on this site.